Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

Drugs and Therapy Perspectives

Volumn 27, Issue 10, 2011, Pages 24-26

  Simoens, Steven ^a   Cassiman, David ^b   Picavet, Eline ^a   Dooms, Marc ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 PHENYLBUTYRIC ACID; AMINOLEVULINIC ACID; BETAINE; MERCAPTAMINE; ORPHAN DRUG; ZINC ACETATE;

ARTICLE; BELGIUM; COST BENEFIT ANALYSIS; CYSTINOSIS; DRUG COST; EATON LAMBERT SYNDROME; GLIOBLASTOMA; HEALTH CARE COST; HOMOCYSTINURIA; RARE DISEASE; UREA CYCLE DISORDER; WILSON DISEASE;

EID: 80052487434     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.2165/11601640-000000000-00000     Document Type: Article

References (15)

1. Regulation (EC) no. 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official J Eur Commun 2000; L 18/1
2. Orphanet: the portal for rare diseases and orphan drugs [online]. Available from URL: http://www.orpha.net [Accessed 2011 May 9]
3. Denis A, Mergaert L, Fostier C, et al. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 2010; 13 (2): 295-301
4. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23 (1): 36-42 (Pubitemid 46648298)
5. Regnstrom J, Koenig F, Aronsson B, et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur J Clin Pharmacol 2010; 66 (1): 39-48
6. Boon W, Moors E. Exploring emerging technologies using metaphors: a study of orphan drugs and pharmacogenomics. Soc Sci Med 2008; 66 (9): 1915-27
7. Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: orphan designation status influences price. Appl Health Econ Health Policy 2011; 9 (4): 1-5
8. Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984; 34 (10): 1324-30 (Pubitemid 14047242)
9. ONeil M, Heckelman P, Koch C, et al. The Merck Index: an encyclopedia of chemicals, drugs and biologicals. Whitehouse Station (NJ): Merck Research Laboratories; 2006
10. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42 (3): 518-25
11. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981; 99 (3): 467-72 (Pubitemid 11029956)
12. Roy LP, Pollard AC. Cysteamine therapy for cystinosis. Lancet 1978; II (8092 Pt 1): 729-30 (Pubitemid 9040750)
13. Tuchman M, Knopman DS, Shih VE. Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Arch Neurol 1990; 47 (10): 1134-7 (Pubitemid 20326674)
14. Hoogenraad TU, Van den Hamer CJ, Koevoet R, et al. Oral zinc in Wilsons disease. Lancet 1978; 2 (8102): 1262
15. Rinaldi A. Adopting an orphan. EMBO Rep 2005; 6 (6): 507-10. (Pubitemid 40973956)